Monograph of Isoniazid

Introduction

Isoniazid (INH) is a first‑line antitubercular agent that has been instrumental in the control of tuberculosis (TB) worldwide. It is a small, hydrazide‑containing compound, chemically defined as p‑nicotylhydrazide, and is administered orally in a free base or salt form. The drug exerts its therapeutic effect by targeting the mycobacterial cell wall biosynthesis pathway, specifically inhibiting the enzyme mycolic acid synthesis, which is essential for the survival of Mycobacterium tuberculosis (M. tuberculosis).

The discovery of INH can be traced back to the late 1930s, when the British chemist Edward R. J. Mitchell and colleagues identified its antitubercular activity. Its widespread adoption began in the 1950s, following the need for more effective and shorter treatment regimens. Since then, INH has remained a cornerstone of TB therapy, both in monotherapy during the intensification phase of treatment and as part of combination regimens to prevent the emergence of drug resistance.

For medical and pharmacy students, a deep understanding of isoniazid is essential due to its ubiquitous presence in TB treatment protocols, its complex pharmacokinetic profile, and its potential for significant drug interactions and adverse effects. Mastery of the concepts discussed herein will enable students to predict therapeutic outcomes, manage side‑effects, and apply evidence‑based dosing strategies in clinical practice.

• Define the structural, pharmacological, and clinical characteristics of isoniazid.
• Explain the mechanistic basis of isoniazid’s antitubercular activity.
• Describe the pharmacokinetic parameters and influencing factors of isoniazid.
• Identify common adverse reactions and drug interactions associated with isoniazid.
• Apply knowledge of isoniazid to case‑based clinical scenarios in TB management.

Fundamental Principles

Core Concepts and Definitions

Isoniazid is classified as a hydrazide antitubercular agent. Its chemical formula is C₆H₇N₃O₂, and it is available commercially as the hydrazide free base or as the hydrazide monohydrate salt. The drug’s primary mechanism involves the inhibition of mycolic acid biosynthesis, leading to impaired cell wall integrity and eventual bacterial cell death. The term mycolic acid refers to long‑chain fatty acids that are integral components of the mycobacterial cell wall, conferring hydrophobicity and resistance to desiccation.

In the context of TB therapy, isoniazid is typically used in combination with other first‑line agents such as rifampin, pyrazinamide, and ethambutol. The regimen often follows the standard 6‑month schedule: a 2‑month intensive phase with all four drugs, followed by a 4‑month continuation phase with isoniazid and rifampin. This sequence leverages isoniazid’s bactericidal activity during the initial phase and its sustained action during the continuation phase.

Theoretical Foundations

The pharmacodynamics of isoniazid rely on its conversion to a reactive metabolite that interferes with the InhA enzyme, a critical component of the fatty acid synthase II system. The inhibition of InhA reduces the synthesis of mycolic acids, thereby compromising cell wall integrity. The theoretical framework of this interaction is grounded in enzyme inhibition kinetics, where the drug’s active metabolite competes with the natural substrate for the enzyme’s active site, leading to a decrease in enzyme activity proportional to drug concentration.

Pharmacokinetics of isoniazid are characterized by rapid absorption following oral administration, with maximum plasma concentrations (C_max) reached within 1–2 hours. The drug’s elimination follows first‑order kinetics, with a half‑life (t_1/2) ranging from 1 to 4 hours in healthy adults. Clearance (Cl) and volume of distribution (V_d) are critical parameters for understanding dosing intervals and steady‑state concentrations. The following relationship holds: AUC = Dose ÷ Clearance, where AUC denotes area under the concentration–time curve.

Key Terminology

• Hydrazide – a functional group containing a –NH–NH₂ moiety.
• Mycolic Acid – long‑chain fatty acids integral to mycobacterial cell wall.
• InhA – an enzyme involved in mycolic acid synthesis.
• Metabolism – hepatic conversion of isoniazid to acetylisoniazid via N‑acetyltransferase (NAT2).
• Acetylator Phenotype – classification of individuals as slow, intermediate, or fast acetylators based on NAT2 genotype.
• Adverse Effect – any undesired pharmacological response, e.g., hepatotoxicity, peripheral neuropathy.
• Drug Interaction – alteration of isoniazid’s pharmacokinetics or pharmacodynamics due to co‑administered agents.

Detailed Explanation

Pharmacodynamics

The bactericidal activity of isoniazid is primarily mediated by the inhibition of mycolic acid synthesis. The active metabolite, generated by hepatic acetylation, binds to the F_ad domain of InhA, preventing the enzyme from catalyzing the addition of fatty acid chains to the mycolic acid precursor. This inhibition leads to a rapid decline in the integrity of the cell wall, rendering the bacteria susceptible to host immune responses and subsequent cell lysis.

In addition to its direct enzymatic inhibition, isoniazid may exert a synergistic effect when combined with other first‑line agents. For instance, rifampin enhances the bactericidal effect by inhibiting RNA polymerase, while pyrazinamide and ethambutol target other aspects of mycobacterial metabolism. The combined effect is additive, reducing the likelihood of resistance development.

Pharmacokinetics

Absorption

Following oral ingestion, isoniazid is absorbed in the upper gastrointestinal tract with high efficiency. The absorption rate is influenced by food intake; high‑fat meals may delay gastric emptying but do not significantly reduce overall bioavailability. The absolute bioavailability is approximately 90%, indicating that most of the administered dose reaches systemic circulation intact.

Distribution

Isoniazid distributes widely throughout body tissues, including the lungs, liver, kidneys, and spleen. Its volume of distribution (V_d) is estimated at 0.5–0.8 L/kg, reflecting moderate penetration into tissues. The drug’s lipophilic nature facilitates passage through cell membranes, ensuring adequate exposure to mycobacterial lesions within granulomatous tissues.

Metabolism

The primary metabolic pathway for isoniazid involves hepatic acetylation mediated by N‑acetyltransferase 2 (NAT2). This phase II reaction converts isoniazid to acetylisoniazid, which is then further hydrolyzed to acetylhydrazine. The acetylation rate is genetically determined, leading to distinct acetylator phenotypes:

• Fast acetylators: rapid metabolism, lower plasma concentrations, increased risk of hepatotoxicity at standard doses.
• Slow acetylators: reduced metabolism, higher plasma concentrations, increased risk of neurotoxicity.

In addition to acetylation, isoniazid undergoes N‑hydroxylation and glucuronidation, pathways that contribute to its elimination. The overall hepatic clearance is variable but typically accounts for 80% of total clearance. Renal excretion plays a secondary role, contributing to the elimination of unchanged drug and metabolites.

Elimination

The elimination of isoniazid follows first‑order kinetics, with a half‑life (t_1/2) of approximately 1–4 hours in healthy adults. In individuals with hepatic impairment or altered acetylator status, the half‑life may extend to 8–12 hours or more. The relationship between dose, clearance, and exposure is captured by the equation: AUC = Dose ÷ Clearance. The clearance (Cl) can be approximated by the formula: Cl = (V_d ÷ t_1/2) × ln 2, where ln 2 is the natural logarithm of 2.

Factors Affecting Pharmacokinetics

1. Genetic Polymorphism (NAT2) – Determines acetylator phenotype, influencing both efficacy and toxicity.
2. Age – Neonates and the elderly may exhibit reduced hepatic clearance, leading to prolonged exposure.
3. Liver Function – Hepatic disease impairs metabolism, increasing systemic concentrations.
4. Drug–Drug Interactions – Concomitant agents such as rifampin induce hepatic enzymes, accelerating isoniazid clearance.
5. Alcohol Consumption – Chronic alcohol use can induce hepatic enzymes, altering isoniazid metabolism.

Mathematical Relationships and Models

In therapeutic drug monitoring (TDM) of isoniazid, the following relationships are frequently employed:

• Peak concentration (C_max) correlates with the dose and absorption rate: C_max ≈ (Dose ÷ V_d) × (1 ÷ (1 – e^–k_at)) where k_a is the absorption rate constant.
• Steady‑state concentration (C_ss) can be predicted by C_ss = (k_in ÷ k_el), where k_in is the infusion or dosing rate and k_el is the elimination rate constant.
• The accumulation factor (R) for oral dosing at interval τ is R = 1 ÷ (1 – e^–k_elτ), indicating the degree of drug accumulation over successive doses.

Factors Influencing Isolated Drug Response

Individual patient characteristics markedly influence isoniazid pharmacodynamics. For instance, slow acetylators may experience enhanced bactericidal activity due to higher plasma concentrations but also face increased risk of peripheral neuropathy. Conversely, fast acetylators may require dose adjustments to maintain therapeutic exposure. Additionally, concomitant use of vitamin B₆ (pyridoxine) is essential to mitigate neurotoxicity, as isoniazid depletes pyridoxine by forming inactive complexes.

Clinical Significance

Role in TB Therapy

Isoniazid remains a pivotal component of both short‑course and multidrug TB treatment regimens. Its bactericidal activity during the initial intensive phase is crucial for rapid reduction in bacterial load, which decreases the risk of relapse and emergence of drug resistance. The drug’s inclusion in the continuation phase sustains therapeutic pressure, ensuring complete eradication of residual bacilli.

Prevention of Drug Resistance

Monotherapy with isoniazid alone is strongly discouraged, as it fosters the rapid development of resistant mycobacterial strains. Combination therapy dilutes the selective pressure on any single drug target, thereby reducing the probability of resistance. Pharmacodynamic synergy between isoniazid, rifampin, pyrazinamide, and ethambutol further enhances bacterial killing.

Adverse Reactions

Common adverse effects include hepatotoxicity, peripheral neuropathy, and hypersensitivity reactions. Hepatotoxicity may manifest as asymptomatic elevations in serum transaminases or, less frequently, as acute hepatitis. The risk is higher in slow acetylators, older adults, and patients with pre‑existing liver disease. Peripheral neuropathy arises from pyridoxine depletion and can be mitigated by routine supplementation. Hypersensitivity reactions, though rare, may present as rash, fever, or eosinophilia and warrant prompt discontinuation.

Drug Interactions

Several pharmacokinetic and pharmacodynamic interactions are clinically relevant. Rifampin, a potent inducer of hepatic cytochrome P450 enzymes, increases the clearance of isoniazid, potentially lowering plasma concentrations. Conversely, isoniazid inhibits the metabolism of certain drugs, such as carbamazepine, leading to increased plasma levels. Vitamin B₆ supplementation does not interfere with isoniazid metabolism but is essential for preventing neurotoxicity. Alcohol consumption may potentiate hepatotoxicity and should be avoided or limited.

Clinical Applications/Examples

Case Scenario 1: Newly Diagnosed Pulmonary TB

A 32‑year‑old male presents with chronic cough, night sweats, and weight loss. Sputum smears are positive for acid‑fast bacilli. Hepatic function tests are within normal limits. The standard regimen of isoniazid (300 mg) and rifampin (600 mg) is initiated. Over the next week, liver enzymes rise modestly, prompting the addition of pyridoxine (50 mg) daily. The patient tolerates the regimen, and sputum cultures convert to negative after 2 months.

Case Scenario 2: TB in a Patient with Chronic Hepatitis

A 55‑year‑old female with chronic hepatitis B requires TB therapy. She is a slow acetylator (determined by NAT2 genotyping). The isoniazid dose is reduced to 200 mg daily to mitigate hepatotoxicity. Hepatic enzymes are monitored weekly, and pyridoxine is supplemented. Upon normalization of liver function, the dose is increased to 300 mg daily, and treatment continues for 6 months with favorable outcomes.

Case Scenario 3: Drug–Drug Interaction with Antiretroviral Therapy

A 40‑year‑old HIV‑positive patient on a protease inhibitor regimen develops active TB. Rifampin is co‑administered, leading to reduced plasma concentrations of the protease inhibitor due to enzyme induction. To maintain adequate antiretroviral levels, the protease inhibitor dose is increased, and therapeutic drug monitoring is performed. Isoniazid is continued at a standard dose, with close monitoring of liver enzymes and pyridoxine supplementation.

Problem‑Solving Approach

1. Assess Acetylator Status – Genotype or phenotypically determine NAT2 status to guide dosing.
2. Monitor Hepatic Function – Baseline and periodic liver enzyme testing to detect early hepatotoxicity.
3. Supplement Vitamin B₆ – Provide pyridoxine to prevent peripheral neuropathy.
4. Adjust for Interactions – Modify doses of interacting agents (e.g., rifampin, antiretrovirals) based on known hepatic enzyme induction or inhibition.
5. Implement TDM – Measure plasma C_max or AUC in patients with variable pharmacokinetics to ensure therapeutic exposure.

Summary / Key Points

• Isoniazid is a hydrazide antitubercular agent essential for TB treatment regimens.
• Its mechanism involves inhibition of mycolic acid synthesis via the InhA enzyme.
• Rapid oral absorption and moderate tissue distribution characterize its pharmacokinetics.
• Hepatic acetylation by NAT2 determines acetylator phenotype, influencing both efficacy and toxicity.
• First‑order elimination with a half‑life of 1–4 hours is modulated by hepatic function and drug interactions.
• Common adverse reactions include hepatotoxicity and peripheral neuropathy; routine pyridoxine supplementation mitigates neurotoxicity.
• Drug interactions, especially with rifampin and antiretrovirals, necessitate dose adjustments and therapeutic drug monitoring.
• Clinical scenarios illustrate the importance of individualized dosing, monitoring, and management of side effects.
• Key pharmacokinetic relationships: AUC = Dose ÷ Clearance; C_max ≈ (Dose ÷ V_d) × (1 ÷ (1 – e^–k_at)).
• Therapeutic drug monitoring can optimize dosing in patients with altered pharmacokinetics or drug interactions.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.